It has been observed that post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis (PEP) occurs in up to 11% of pediatric patients. To date, no prospective study has evaluated an intervention to prevent PEP in children. It’s uncertain if such a research is even possible. The study’s goal was to assess the feasibility of investigating IV ibuprofen for PEP prophylaxis in the pediatric population. This was a feasibility study that was randomized, double-blind, and placebo-controlled. Patients under the age of 19 who had ERCP were randomly assigned to receive 10 mg/kg IV ibuprofen or placebo at the time of the procedure. PEP was the major result. Secondary outcomes were rates of post-ERCP hemorrhage and other procedural and medication-related side events. A total of 58 individuals were randomly assigned to receive either IV ibuprofen or a placebo. Except for the fact that patients in the placebo group tended to weigh less, pre- and post-procedure characteristics were not substantially different between the groups. PEP consisted of seven episodes. PEP was found less frequently in the Ibuprofen group than in the control group, although this difference was not statistically significant.

The mean postprocedural abdominal pain scores in the IV Ibuprofen group were considerably lower than in the control group, and the number of patients who experienced increasing stomach pain after the operation was much lower in the ibuprofen group than in the control group. There were no statistically significant differences in procedure- or drug-related adverse events.

Reference:https://journals.lww.com/jpgn/Fulltext/2020/01000/IV_Ibuprofen_for_Prevention_of_Post_ERCP.22.aspx